VAN-ZOLMITRIPTAN TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
09-04-2015
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
ZOLMITRIPTAN
Tillgänglig från:
VANC PHARMACEUTICALS INC
ATC-kod:
N02CC03
INN (International namn):
ZOLMITRIPTAN
Dos:
2.5MG
Läkemedelsform:
TABLET
Sammansättning:
ZOLMITRIPTAN 2.5MG
Administreringssätt:
ORAL
Enheter i paketet:
100
Receptbelagda typ:
Prescription
Terapiområde:
SELECTIVE SEROTONIN AGONISTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0134381001; AHFS:
Bemyndigande status:
CANCELLED PRE MARKET
Tillstånd datum:
2019-07-31
Produktens egenskaper
Page | 1
PRODUCT MONOGRAPH
PR
VAN-ZOLMITRIPTAN
ZOLMITRIPTAN TABLETS
2.5 MG
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
MANUFACTURER AND DISTRIBUTOR:
Vanc Pharmaceuticals Inc.
Date of Preparation: March 25, 2015
Unit-210, 2639 Viking Way
Richmond, BC V6V 3B7
www.vancpharm.com
Control# 182335
Page | 2
TABLE OF CONTENTS
PRODUCT MONOGRAPH
......................................................................................................
1
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
5
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
17
DOSAGE AND ADMINISTRATION
................................................................................
19
OVERDOSAGE
..................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 20
STORAGE AND STABILITY
............................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
24
PHARMACEUTICAL INFORMATIO
Läs hela dokumentet
